Tryptamine Therapeutics Ltd
TYP
Company Profile
Business description
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Contact
C/o Bio101 Financial Advisory Pty Ltd
697 Burke Road, Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920475
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
50
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,822.40 | 19.50 | -0.22% |
| CAC 40 | 7,696.27 | 58.28 | -0.75% |
| DAX 40 | 23,787.45 | 146.68 | -0.61% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,822.91 | 0.29 | -0.00% |
| HKSE | 23,864.78 | 51.28 | -0.21% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,560.88 | 250.00 | -0.63% |
| NZX 50 Index | 12,764.95 | 1.65 | -0.01% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,584.80 | 18.20 | -0.21% |
| SSE Composite Index | 3,471.90 | 0.42 | -0.01% |